Skip to main content

Table 1 Antibacterial treatments received within 72 h prior to starting study treatment in ASPECT-NP participantsa who were failing prior antibacterial therapy

From: Outcomes in participants with failure of initial antibacterial therapy for hospital-acquired/ventilator-associated bacterial pneumonia prior to enrollment in the randomized, controlled phase 3 ASPECT-NP trial of ceftolozane/tazobactam versus meropenem

Antibacterial treatment, n (%)

C/T (N = 53)

MEM (N = 40)

Piperacillin/tazobactam

16 (30.2)

17 (42.5)

Fluoroquinolones

15 (28.3)

12 (30.0)

Third/fourth-generation cephalosporins

13 (24.5)

16 (40.0)

 Cefepime

4 (7.5)

3 (7.5)

 Cefotaxime

0

4 (10.0)

 Ceftriaxone

9 (17.0)

6 (15.0)

Amoxicillin/clavulanate

6 (11.3)

2 (5.0)

Ampicillin/sulbactam

5 (9.4)

1 (2.5)

Aminoglycosides

7 (13.2)

4 (10.0)

 Amikacin

5 (9.4)

4 (10.0)

Macrolides

3 (5.7)

1 (2.5)

Carbapenems

2 (3.8)

3 (7.5)

Cefoperazone/sulbactam

4 (7.5)

3 (7.5)

  1. Includes all systemic antibacterial treatments with potential gram-negative activity administered within 72 h prior to starting study treatment; participants may have received multiple treatments sequentially and/or concomitantly
  2. C/T Ceftolozane/tazobactam, MEM Meropenem, vHABP Ventilated hospital-acquired bacterial pneumonia, VABP Ventilator-associated bacterial pneumonia
  3. aIn ≥ 3 participants
Back to article page

Critical Care

ISSN: 1364-8535